| Title: |
Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus |
| Authors: |
Fidler, S; Fox, J; Tipoe, T; Longet, S; Tipton, T; Abeywickrema, M; Adele, S; Alagaratnam, J; Ali, M; Aley, PK; Aslam, S; Balasubramanian, A; Bara, A; Bawa, T; Brown, A; Brown, H; Cappuccini, F; Davies, S; Fowler, J; Godfrey, L; Goodman, AL; Hilario, K; Hackstein, C-P; Mathew, M; Mujadidi, YF; Packham, A; Petersen, C; Plested, E; Pollock, KM; Ramasamy, MN; Robinson, H; Robinson, N; Rongkard, P; Sanders, H; Serafimova, T; Spence, N; Waters, A; Woods, D; Zacharopoulou, P; Barnes, E; Dunachie, S; Goulder, P; Klenerman, P; Winston, A; Hill, AVS; Gilbert, SC; Carroll, M; Pollard, AJ; Lambe, T; Ogbe, A; Frater, J |
| Publisher Information: |
Oxford University Press |
| Publication Year: |
2023 |
| Collection: |
Oxford University Research Archive (ORA) |
| Description: |
Background People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data on longer term responses and the impact of a booster dose. Methods Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed 12 months later by a third heterologous vaccine dose. Participants had undetectable viraemia on ART and CD4 counts >350 cells/µL. Immune responses to the ancestral strain and variants of concern were measured by anti-spike immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA), MesoScale Discovery (MSD) anti-spike platform, ACE-2 inhibition, activation induced marker (AIM) assay, and T-cell proliferation. Findings In total, 54 participants received 2 doses of ChAdOx1 nCoV-19. 43 received a third dose (42 with BNT162b2; 1 with mRNA-1273) 1 year after the first dose. After the third dose, total anti-SARS-CoV-2 spike IgG titers (MSD), ACE-2 inhibition, and IgG ELISA results were significantly higher compared to Day 182 titers (P < .0001 for all 3). SARS-CoV-2 specific CD4+ T-cell responses measured by AIM against SARS-CoV-2 S1 and S2 peptide pools were significantly increased after a third vaccine compared to 6 months after a first dose, with significant increases in proliferative CD4+ and CD8+ T-cell responses to SARS-CoV-2 S1 and S2 after boosting. Responses to Alpha, Beta, Gamma, and Delta variants were boosted, although to a lesser extent for Omicron. Conclusions In PWH receiving a third vaccine dose, there were significant increases in B- and T-cell immunity, including to known variants of concern (VOCs). |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://doi.org/10.1093/cid/ciac796 |
| DOI: |
10.1093/cid/ciac796 |
| Availability: |
https://doi.org/10.1093/cid/ciac796; https://ora.ox.ac.uk/objects/uuid:dd11825b-6754-4c1e-8184-4c9e52c9b878 |
| Rights: |
info:eu-repo/semantics/openAccess ; CC Attribution (CC BY) |
| Accession Number: |
edsbas.DEA0F377 |
| Database: |
BASE |